Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

The Role of Regulatory B Cell-Like Malignant Cells and Treg Cells in the Mouse Model of BCL1 Tumor Dormancy

  • Andrew BitMansour,

    Affiliation Department of Immunology and Cancer Immunobiology Center University of Texas Southwestern Medical Center at Dallas, Texas, United States of America

  • Laurentiu M. Pop,

    Affiliation Department of Immunology and Cancer Immunobiology Center University of Texas Southwestern Medical Center at Dallas, Texas, United States of America

  • Ellen S. Vitetta

    Affiliation Department of Immunology and Cancer Immunobiology Center University of Texas Southwestern Medical Center at Dallas, Texas, United States of America

The Role of Regulatory B Cell-Like Malignant Cells and Treg Cells in the Mouse Model of BCL1 Tumor Dormancy

  • Andrew BitMansour, 
  • Laurentiu M. Pop, 
  • Ellen S. Vitetta


Cancer dormancy is a clinical state in which residual tumor cells persist for long periods of time but do not cause detectable disease. In the mouse B cell lymphoma model (BCL1), dormancy can be induced and maintained by immunizing mice with a soluble form of the IgM expressed on the surface of the tumor cells. Immunization induces an anti-idiotype antibody response that maintains dormancy. Mice with dormant tumor have low numbers of BCL1 cells in their spleens that divide and are killed at the same rate. When the anti-Id antibodies wane, the tumor cells grow rapidly and kill the host. Spleens from tumor-bearing mice contain both effector (CD4+ and CD8+) and regulatory T cells (Tregs). In other tumor models, it has been reported that Tregs promote tumor progression by preventing effector cells from killing the tumor. In this report, we demonstrate that the tumor site with rapidly dividing BCL1 cells has fewer Tregs than the tumor site harboring dormant BCL1 cells. In both cases, the Tregs were equally suppressive in vitro. In spleens from mice with actively growing tumor, CD8+ but not CD4+ T cells were virtually absent. In vitro analysis demonstrated a tumor-mediated elimination of CD8+ T cells that was contact dependent and involved the caspase-3 pathway. Most importantly, we found that the BCL1 cells expressed characteristics of B10 regulatory B cells, i.e., they were CD1dhiCD5+ and secreted high levels of IL-10. These BCL1 tumor cells can inhibit anti-tumor immune responses by depleting CD8+ effector T cells.


The tumor site represents a complex microenvironment where malignant cells reconstruct the milieu to promote tumor growth while anti-tumor immune responses aim to eliminate tumor cells. When effective, anti-tumor immunity can induce quiescence or dormancy in tumor cells. Cancer dormancy is a clinical state in which tumor cells are present in clinically healthy subjects but are maintained in a steady state; yet relapses can occur years later [1]. Indeed, many cancer patients who are in complete remission have circulating tumor cells (CTCs) in their blood or bone marrow [2, 3] and the presence of these cells suggests that tumor is present but probably dormant [4].

We have extensively studied tumor immunity in the mouse BCL1 model of tumor dormancy [57]. This is a relatively unique model where tumor dormancy is mediated by antibody against the idiotype (Id) of IgM/IgD expressed on the BCL1 cells. When inoculated into non-immunized BALB/c mice, the BCL1 tumor cells initially proliferate in the spleen, resulting in pronounced splenomegaly. Tumor cells are later found in blood and lymph nodes. Immunization with the BCL1 IgM-Id induces high titers of anti-Id antibodies that provide long-lasting protection against subsequent challenge with BCL1 tumor cells. Although the tumor cells grow for a short time in the immunized mice, tumors then regress and persist in a constant number (106−107) in the spleen. Over time, tumor cells can proliferate in some of the mice and this “relapse” has been attributed to several factors including decreases in anti-Id antibody titers and mutations in the signaling pathway by which the anti-Id inhibits tumor growth [7].

Cellular immunity against the BCL1 tumor can enhance dormancy as suggested by the fact that interferon-gamma (IFN-γ) secreted by Th1 cells or cells of the innate immune system prolong immunity mediated by anti-Id antibody [8]. However, effective immunity can also be induced in SCID mice treated with anti-Id antibodies, thus demonstrating that T cell-mediated cellular immunity is not absolutely required [9].

A formidable obstacle confronted in cancer therapy is the ability of tumor cells to evade anti-tumor immunity. This occurs partially through the tumor-mediated induction of suppressor cells within the tumor microenvironment. Immune-suppressor lymphocyte subsets such as regulatory T cells (Tregs) and B cells (Bregs) normally maintain systemic homeostasis by preventing autoimmunity and alleviating inflammation following the resolution of infection or injury [1012]. However, tumor cells can manipulate these regulatory lymphocyte subsets to inhibit anti-tumor immune responses. Infiltration of Tregs in the tumor microenvironment has been reported to induce immune tolerance and thus promote tumor progression [1316]. Moreover, increased numbers of Tregs have also been shown to correlate with a poor prognosis in cancer patients [16,17].

The mechanisms by which Tregs suppress effector immune responses include direct cell contact [18,19] and secretion of immunosuppressive cytokines [2022]. B cells have also been shown to control immune hyperactivity primarily through the production of IL-10 [23]. Such immunomodulatory “Bregs” can induce Tregs, downregulate TH1 cytokines, and limit TH17 differentiation [2427]. Therefore, Bregs may also contribute to tumor progression.

In this study, we examined the role of regulatory cells in tumor progression. In the BCL1 tumor model dormant vs. active tumor environments could be examined in parallel. Our aim was to determine whether the presence of anti-tumor immune responses diminished the putative role of Tregs on tumor progression. Unexpectedly, we found higher numbers of Tregs in the spleens of mice harboring dormant tumor cells, as compared to the spleens of their non-dormant counterparts where tumor cells were rapidly expanding. Yet, Tregs isolated from both tumor microenvironments suppressed the proliferation of effector T cells in vitro equally well. Our results show that in the BCL1 tumor, accumulation of Tregs in the tumor site did not directly correspond with tumor growth and thus may be only one correlate of disease progression. Furthermore, we observed that the BCL1 tumor cells exhibited the phenotype and cytokine profile of the B10 subset of Bregs and they directly suppressed CD8+ T cells. Therefore, the tumor cells were the most abundant inhibitory cell subset in the tumor microenvironment. Our results suggest that cross-talk between malignant Bregs and different types of normal effector T cells might be extremely important in the growth vs. stasis of Breg-like tumors, such as chronic lymphocytic leukemia (CLL), in humans. Although this is a single tumor model, it raises important questions about the interactions between B lymphoid tumors and both effector and regulatory T cells in their environment.

Materials and Methods


BALB/c mice were bred and maintained in the animal colony at the University of Texas Southwestern Medical Center (UTSW) at Dallas. This study was designed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the protocol was approved by the UTSW Institutional Animal Care and Use Committee (IACUC). Animals were monitored daily by the animal facility caretakers and weekly by a staff veterinarian. Mice that became unexpectedly ill or exhibited signs of distress were removed from the study, anesthetized then sacrificed by cervical dislocation.

Purification of the Id+ BCL1 IgM

A BCL1 hybridoma cell line (BCL1X x63) that secretes the Id+ IgM and IgG1 (MOPC-21) was used for generating and purifying the BCL1 IgM, as described previously (5). Cells were expanded in DMEM (Sigma; St. Louis, MI) supplemented with 10% fetal bovine serum (FBS) (Hyclone; Logan, UT) in a standard incubator (37°C, 5% CO2) for 5–7 days. The supernatants were collected and mixed with a saturated ammonium sulfate solution (Sigma) to a final concentration of 30% and total protein was allowed to precipitate overnight at 4°C. The precipitate was dissolved in Millipore water, and dialyzed [MWCO 12–14,000] (Spectrum Labs; Irving, TX) against PBS, pH 7.4. The IgM was purified by chromatography on an Ultrogel AcA 34 polyacrylamide matrix column (Sigma).

Conjugation of the BCL1-IgM to Keyhole Limpet Hemocyanin (KLH)

BCL1 IgM and KLH (CalBiochem; Los Angeles, CA) were each adjusted to 1 mg/mL with PBS, combined at a 1:1 ratio, mixed with 1.25% glutaraldehyde (Fluka AG; New York, NY), and incubated for 4 hours with continuous mixing. The conjugate solution was dialyzed against PBS at pH 7.4 and aliquots were stored at -80°C.

Emulsification of the BCL1/KLH conjugate in Complete Freund’s adjuvant (CFA) and immunization of mice

For each immunization, 100 μg BCL1-Id IgM/KLH was combined with an equal volume of CFA (100 μL) (Sigma), emulsified in a mixer (Spex; Metuchen, NJ), and drawn into a 1 cc glass tuberculin syringe (BD Biosciences) fitted with a 25 gauge x 5/8” needle (BD Biosciences; Franklin Lakes, NJ). Female BALB/c mice (10–14 weeks) were injected subcutaneously in their lower and upper flanks (100 μL/side) on D-45 and D-38, and under the nape of the neck (200 μL) on D-28 (relative to the day of tumor inoculation).

BCL1 tumor inoculation

A frozen aliquot of spleen cells from BCL1 tumor-bearing mice was thawed and suspended in cold, sterile HBSS (Gibco; Gaithersburg, MD). Mice were injected with 5 x 104 cells/mouse into the peritoneum 28 days (D0) after the third and final immunization.

Examination of mice for dormancy or splenomegaly

Beginning at three weeks after the injection of tumor cells (D+21), mice were palpated twice weekly for splenomegaly. Mice were assigned a spleen index (SI) of 1–4 corresponding to increasing spleen size, as described previously [7]. Briefly, an SI = 1 corresponds to a normal spleen. A spleen that extends to the mid-line of the abdomen harbors dormant tumor cells and is assigned as SI < 2.5. Spleens that extend beyond the midline indicate active proliferation of the BCL1 tumor cells and have an SI > 2.5. Splenomegaly occurs between days 19 to 43 after injecting BCL1 tumor cells. No splenomegaly was detected in immunized mice at D+60 so this was established as a cutoff point for the designation of dormancy [28].

Phenotypic analysis of leukocyte subsets by flow cytometry

Mice were sacrificed after 60 days and spleens, inguinal and mesenteric lymph nodes were harvested and homogenized into single cell suspensions using HBSS + 2% FBS (Gibco; Gaithersburg, MD). Spleen cells were further treated with ammonium chloride lysing solution to remove erythrocytes. The following anti-mouse antibodies were used for immunophenotyping: anti-CD1d (1D1) (BD Pharmingen; San Diego, CA), anti-CD3 (145-2C11) (BD Pharmingen), anti-CD4 (GK1.5) (eBioscience, San Diego, CA), anti-CD5 (53–7.3) (BD Pharmingen), anti-CD8 (53–6.7) (eBioscience), anti-CD11b (M1/70) (eBioscience), anti-CD19 (6D5) (Caltag Laboratories; Burlingame, CA), anti-CD25 (PC61) (BD Pharmingen), anti-Ter119 (TER-119) (eBioscience), anti-B220 (RA3-6B5) (BD Pharmingen), anti-DX5 (DX5) (eBioscience), anti-Gr-1 (RB6-8C5) (eBioscience), and anti-FoxP3 (FJK-16s) (eBioscience). Staining for FoxP3 was performed according to the manufacturer’s protocol (eBioscience). All samples were acquired on a FACSCalibur flow cytometer (BD Biosciences; San Jose, CA) and analyzed by FlowJo software (Ashland, OR).

Purification of CD4+, CD8+, and Treg cells from the spleens of donor mice

To purify CD4+ T cells and Treg cells from spleens, erythrocytes were lysed and these cells were magnetically enriched following the manufacturer’s protocol (StemCell Technologies; Vancouver, Canada). To sort Treg cells, the CD4+ -enriched spleen cells were further stained for cell surface markers using anti-CD4 (GK1.5), anti-CD25 (PC61), and a “lineage cocktail” consisting of anti-CD11b (M1/70), anti-B220 (RA3-6B5), and anti-Ter119 (TER-119). Cell sorting was performed on a FACSAria (BD Biosciences). To purify CD8+ cells, spleen cells were stained with a cocktail of biotin-labeled antibodies against non-CD8 cell markers [CD4 (RM 4.40), CD11b, B220, CD19, DX5, I-A/IE] and magnetically purified using streptavidin microbeads according to the manufacturer’s protocol (Miltenyi Biotec; Auburn, CA).

Treg cell suppression assays

Sorted Tregs were co-cultured in graded doses with purified “responder” CD4+, CD8+, or BCL1.3B3 cells, the in vitro-adapted cell line of BCL1 tumor cells [29]. Responder cells were cultured in 96-well plates (5 x 104 cells/well) with irradiated BALB/c spleen cells as a source of antigen-presenting cells (50 Gy) and 4 μg/mL anti-CD3 (BioLegend; San Diego; CA) in RPMI medium (Gibco). For thymidine incorporation, 3-day cultures were pulsed overnight with 1 μCi [3H] thymidine (PerkinElmer; San Jose, CA), harvested, and counted in a scintillation counter (PerkinElmer). For CFSE dilution, responder cells were labeled with 5μM CFSE (Invitrogen) and co-cultured with Tregs. When necessary, blocking antibodies against IL-10 [JES5-2A5] (BioLegend) and TGF-β [1D11] (R&D Systems; Minneapolis, MN) were added. For Transwell assays, Treg cells were cultured on 0.4 μm inserts (BD Falcon; Bedford, MA).

BCL1-mediated T cell suppression assays

Purified CD8+ cells were labeled with 5 μM CFSE (Molecular Probes; Eugene, OR) and co-cultured with irradiated BALB/c spleen cells (50 Gy), anti-CD3 (2 μg/mL; BioLegend), rIL-2 (50 ng/mL; Roche; Indianapolis, IN) and cultured in graded doses with BCL1 tumor cells in complete medium. BCL1 tumor cells were purified from inguinal lymph nodes of mice with a high tumor burden (SI > 2.5) using biotin-labeled rat anti-BCL1-Id IgM (clone 6A5, a gift from Dr. Freda Stevenson) and streptavidin-conjugated beads (Miltenyi Biotec). For Transwell assays, BCL1 tumor cells were cultured on 0.4 μm inserts (BD Falcon).

Intracellular cytokine staining for IL-10

Spleen cells from mice bearing active BCL1 tumor cells and naïve mice were suspended at 1 x 106 /mL in stimulation medium prepared using RPMI-1640 (Sigma), L-glutamine (Sigma), NEAA (Gibco), Na-pyruvate (Gibco), 10% heat-inactivated FBS β-mercaptoethanol (50 μM; Sigma), LPS (10 μg/mL; Sigma), PMA (Sigma), Ionomycin (500 ng/mL; Sigma), and monensin (2 μM; BioLegend) and incubated for 5 hours at 37°C, 5% CO2. Samples were washed with cold PBS+10%FBS and stained with antibodies against BCL1-Id, CD3 (145-2C11), CD11b (M1/70), Ter119 (TER119) [for tumor cells] and anti-CD19 (6D5) [normal B cells]. Cells were fixed and permeabilized (Perm Buffer; eBioscience) then stained with anti-IL-10 antibody [JES5-2A5] or isotype control (IgG2b; BioLegend) and analyzed on a FACSAria flow cytometer.

Analysis of soluble cytokines and BCL1-Id by ELISA

Serial dilutions of supernatants from 3-day cultures of BCL1.3B3 tumor cells were added to ELISA plates (BD Falcon) coated with rat anti-BCL1-Id. A positive control (previously purified BCL1-Id from our laboratory stocks) was serially diluted and used to generate the standard curve. An Id-IgM myeloma protein of irrelevant specificity (MOPC-104E, Sigma) was used as the negative control. Rabbit anti-mouse IgM μ-chain-HRP (Jackson Immunoresearch; West Grove, PA) was used as the detection antibody with O-phenylenediamine dihydrochloride (OPD) substrate (Thermo Scientific Pierce; Waltham, MA) as the detection solution and plates were read on an ELISA plate reader (Molecular Devices; Sunnyvale, CA). The cytokines IL-1β, IL-4, IL-6, IL-10, TNF-α, and IFN-γ (R&D Systems), and TGF-β (eBioscience) were also quantified by sandwich ELISA according to the manufacturer’s protocol.

Caspase-3 Activation

CD8+ T cells were purified from the spleens of BALB/c mice using magnetic beads according to the manufacturer’s directions (StemCell Technologies) and cultured with irradiated splenocytes, anti-CD3 (2 μg/mL; BioLegend), rIL-2 (50 ng/mL), and graded doses of purified BCL1 tumor cells. Anti-FasL (CD178, BioLegend) was added at 10 μg/mL as indicated. Cells were stained with fluorochrome-conjugated anti-CD8 (eBioscience) and anti-B220 (BD Biosciences) antibodies. Cells were then stained for intracellular caspase-3 (BD Pharmingen) according to the manufacturer’s specifications. Samples were acquired on a FACSCalibur flow cytometer and analyzed using FlowJo software.


Immunization of BALB/c mice with the BCL1 Id+ IgM elicits the production of anti-Id antibody and results in the inhibition of tumor cell growth and the depletion of CD8+ T cells

Immunization of mice with the BCL1-Id+ IgM-KLH conjugate resulted in the production of high titers of anti-Id antibodies, as has been shown previously [30]. Serum titers of anti-Id measured on D+60, the time-point for dormancy, from mice bearing dormant BCL1 tumors were 13-fold higher than those with non-dormant tumor cells on (data not shown). Mice bearing non-dormant tumor cells had significantly more spleen cells than their dormant counterparts (9.5 x 108 vs. 3.4 x 108 respectively, p = 0.0002) (Fig 1A). The BCL1 tumor cells accounted for the difference in the numbers of spleen as mice with non-dormant tumors cells had significantly higher numbers of BCL1 tumor cells than those harboring dormant tumor cells (2.9 x 108 vs. 8.5 x 106, respectively, p = 0.001) (Fig 1B).

Fig 1. Increased BCL1 tumor cell burdens leads to the depletion of CD8+ T cells.

Groups of mice immunized with the BCL1-Id along with non-immunized groups were inoculated with BCL1 tumor cells. Sixty days after tumor challenge, immunophenotyping was performed on spleen cells. (A) The total number of spleen cells from mice that were challenged with BCL1 tumor. (B) The total number of BCL1 tumor cells in the spleen. The total number of (C) CD4+ T cells, and (D) CD8+ T cells in the spleen from all experiment groups. Each group represents a mean of four to eight mice from at least 3 experiments. Data are shown as mean ± SEM (* p < 0.05, **p < 0.005, *** p < 0.0005, ****p < 0.0001; student’s t-test).

We also examined levels of CD4+ and CD8+ T cells in the spleens on D+60. Immunization alone resulted in a significant increase in the total number of CD4+ T cells (4.02 x 107 cells, p = 0.032) relative to controls (2.57 x 107 cells) (Fig 1C) and a modest but not statistically significant increase in the total number of CD8+ T cells (1.42 x 107 cells vs. 0.93x107 cells, p = 0.092) (Fig 1D). In the absence of immunization, the robust proliferation of BCL1 tumor cells in the spleen correlated with in an almost complete elimination of CD8+ T cells relative to controls (9.9-fold reduction, p = 0.001) (Fig 1D). However, CD4+ T cells did not experience a statistically significant reduction (1.1-fold change, p = 0.545) (Fig 1C). In contrast, both the CD4+ and CD8+ T cells in the spleens of mice with dormant tumor remained stable (Fig 1C and 1D). Therefore, active proliferation of tumor cells leads to the elimination of CD8+ T cells from the tumor site. In contrast, dormant tumor cells do not cause a depletion of CD8+ T cells from the tumor site.

Quantification of Treg cells in the spleens of mice with dormant tumor

It has been reported that Tregs infiltrate tumor sites in a wide variety of cancers [1316]. On D+60 we examined the numbers of Tregs in the spleens of mice with dormant vs. actively growing BCL1 tumor cells and the corresponding controls and found notable differences in numbers of Tregs. (Fig 2A). We observed the following: 1. Immunization alone resulted in a significant increase in the total number of Tregs (Fig 2B) but their percentages remained similar to those observed in the spleens from control mice (Fig 2C). 2. The subsequent challenge of immunized mice with BCL1 tumor cells resulted in a reduction in the number of Tregs in the spleen, i.e. spleens from mice with both dormant and actively growing tumor had fewer Tregs (4.2 x 106 cells, p < 0.07 and 3.2 x 106 cells, p = 0.0002, respectively) than mice that were immunized but not injected with tumor cells (6.5x106 cells) (Fig 2B). 3. All mice (with or without immunization) that were inoculated with tumor cells experienced a reduction in Tregs in their spleens relative to their respective controls. Tregs were fewest in mice that received BCL1 tumor cells without prior immunization (1.4 x 106 cells). In this group, Tregs in the spleen constituted only 0.8% of the total lymphocytes compared to 9.9% in control mice (Fig 2C). 4. Overall, the number of Tregs decreased as tumor cells rapidly proliferated in the spleens, suggesting that rapid tumor cell expansion leads to the depletion of Tregs at the tumor site.

Fig 2. Immunization results in an increase in Tregs while BCL1 tumor cell growth reduces Tregs at the tumor site.

(A) Spleen cells from mice immunized with BCL1-Id and inoculated with BCL1 tumor cells were examined for Tregs (CD4+Foxp3+) 60 days after tumor challenge. (B) total number, and (C) percentage of Tregs in the spleen were determined based on the total viable spleen cells. The values are a compilation of at least 3 different experiments with 4–7 mice per group. Representative plots include 8 or more mice per group. Data are shown as mean ± SEM (* p < 0.05, **p < 0.005, *** p < 0.0005, ****p < 0.0001; student’s t-test).

The presence of BCL1 tumor cells in inguinal lymph nodes has no effect on the numbers of different T cells

It has been well documented that spleens contain far more BCL1 cells than other organs even when tumor dormancy is established [28]. Nevertheless, we examined T cells subsets in the draining lymph nodes to determine if they were also altered by the presence of tumor cells. We found that immunization alone resulted in an increase in Tregs in the inguinal lymph nodes. The percentage of the Tregs in the inguinal nodes of all mice correlated with their spleens. (Fig 3A and 3B). However, unlike the situation in the spleen, the presence of small numbers of BCL1 tumors in the inguinal lymph nodes did not lead to a significant reduction of Tregs as compared to healthy controls. Both the CD4+ and CD8+ T cells in the inguinal lymph nodes were also boosted by immunization. (Fig 3C and 3D). This was likely due to the fact that these nodes drained the sites of injection.

Fig 3. BCL1 tumor cells do not impact regulatory and conventional T cells in the draining lymph nodes.

(A) The total number and (B) percentage of Tregs (CD4+Foxp3+) in the inguinal lymph nodes were examined within each group of mice 60 days after tumor challenge. Healthy control mice were age-matched to the experiment groups. The total number of (C) CD4+ T cells and (D) CD8+ T cells within the inguinal lymph nodes were determined within each group at 60 days after tumor challenge. The values represent a compilation of 1–3 different experiments with 4–13 mice per group. Data are shown as mean ± SEM (* p < 0.05, **p < 0.005, *** p < 0.0005, ****p < 0.0001; student’s t-test).

We also enumerated the T cell subsets in the mesenteric lymph nodes and found no difference in any of the experimental groups examined (data not shown). These results support the hypothesis that a certain threshold of tumor cells is required before T cells are depleted.

Immunization with BCL1-Id does not impair the function of Tregs in the tumor microenvironment

Since Tregs were more prevalent in the spleens from mice with dormant tumor cells as compared to those with actively growing tumor cells, we examined their capacity to inhibit effector T cell proliferation using Treg suppression assays. We observed that Tregs from mice with either dormant or actively growing tumor suppressed the proliferation of naïve CD4+ T cells (Fig 4A). However, Tregs from spleens of mice with actively growing tumor were more potent suppressor cells than those from spleens with dormant tumor cells i.e. they inhibited the proliferation of CD4+ T cells at the lowest ratio (0.25:1). Since the tumor microenvironment can impair effector T cell function, we also isolated CD4+ T cells from the spleens of mice with actively growing tumor mice to use as responder cells. In this case, Tregs from both BCL1 tumor environments performed similarly in their ability to suppress the proliferation of CD4+ T cells suggesting that the tumor microenvironment also contributes to the functionality of effector T cells (Fig 4B).

Fig 4. Tregs from the dormant BCL1 tumor microenvironment maintain their capacity to suppress CD4+ and CD8+ T cells.

Treg suppression assays were performed using CD4+ T cells purified from spleens of (A) naive mice, or (B) BCL1 tumor-inoculated mice. Suppression by Tregs was calculated relative to the samples containing CD4+T cells only (0:1). The data are shown as mean ± SEM from three experiments (* p < 0.05). (C) Tregs were sorted from spleens of mice harboring dormant BCL1 tumor cells and co-cultured with CFSE-labeled CD8+T cells purified from naive mice. Histogram plots are gated on CD8+ cells and the values represent the percent CFSE dilution. Representative plots of 3 independent experiments yielding similar results.

Tregs from mice with dormant tumor cells also inhibited the proliferation of CD8+ T cells, further demonstrating that the induction of dormancy did not impair the function of Tregs. Importantly, Tregs almost completely prevented the proliferation of CD8+ T cells in co-culture (Fig 4C). Treg-induced suppression of CD8+ T cells was also observed when their numbers were adjusted to match the physiological ratios we observed in the spleen (average of 0.4-to-1 from Figs 1D and 2B). Together, these data suggest that Tregs from the mice with both dormant and actively growing tumors suppress the proliferation of CD4+ and CD8+ T cells to the same extent, but that there were more Tregs in the spleens of mice with dormant tumors.

T cell suppression by Tregs requires cell contact

We examined the mechanism by which Tregs suppress CD4+ T cells. Previous reports have shown that different subsets of Tregs can mediate suppression by the secretion of inhibitory cytokines such as IL-10, TGF-β and IL-35 and by direct cell contact [18]. In agreement with other reports [22, 31], our experiments showed that neither the addition of neutralizing anti-IL-10 antibodies nor rIL-10 decreased the in vitro suppressive activity of Tregs (data not shown). Moreover, addition of recombinant IL-10 did not suppress the proliferation of the CD4+ cells in vitro (data not shown). As noted earlier, co-culture of Tregs with CFSE-labeled CD4+ T cells inhibited their proliferation as observed by the lack of CFSE dilution (Fig 5A). However, in trans-well assays in which contact between Tregs and CD4+ T cells was prevented, Treg-induced suppression was lost (Fig 5B) and the proliferation of CD4+ T cells proliferation was similar to that of CD4+ cells in wells containing no Tregs (Fig 5C). These results show that Tregs from the spleens of mice with dormant tumors are functional and maintained their ability to suppress T cells and that suppression requires cell contact.

Fig 5. Tregs suppress CD4+ T cell proliferation by cell contact but do not suppress BCL1 tumor cells.

(A) Tregs from mice harboring dormant BCL1 tumor cells were cultured in equal numbers with CFSE-labeled CD4+ T cells. (B) Tregs were plated onto trans-well inserts and placed in wells containing CFSE-labeled CD4+ T cells in an equal ratio. (C) CFSE-labeled CD4+ T cells were assessed for proliferation in the absence of Tregs. Plots are representative of 3 or more experiments yielding similar results. (D) Graded numbers of Tregs from mice with dormant BCL1 tumor cells were co-cultured with BCL1.3B3 tumor cells. Proliferation of BCL1.3B3 cells in the absence of Tregs (0:1) was considered to be the baseline values. Data represent the average of 3 experiments. E, BCL1-Id+ IgM secreted by BCL1.3B3 cells as measured by ELISA. Data represent the average of 4 experiments.

Tregs cells do not suppress BCL1 tumor cell proliferation or IgM secretion in vitro

Most studies on Treg function have examined their capacity to suppress T cell proliferation. However, it has also been shown that Tregs can directly suppress the proliferation of B cells [24]. Since the immunized mice had a higher ratio of Tregs to BCL1 tumor cells as compared to non-immunized tumor bearing mice, we examined the ability of Tregs to inhibit the proliferation of tumor cells. The baseline proliferation of BCL1 tumor cells in culture (no Tregs added) was measured and used to determine the relative proliferation of BCL1 tumor cells that were co-cultured with Tregs. We found that Tregs co-cultured with equal numbers of BCL1 tumor cells, neither inhibited tumor cell proliferation (Fig 5D) nor induced a statistically significant change in the number of tumor cells.

We next examined the effects of Treg cells on the secretion of IgM by BCL1 tumor cells. Tregs from the spleens of mice with dormant tumors were co-cultured with tumor cells for 3 days after which the media were collected and assayed by ELISA for levels of BCL1-Id+ IgM. As shown in Fig 5E, the addition of Tregs did not inhibit the secretion of IgM by the tumor cells. Therefore, Tregs within the tumor site did not exhibit any direct effects on BCL1 tumor cells that we could measure in vitro.

BCL1 tumor cells exhibit characteristics of Bregs

Bregs are specialized B cells that secrete high levels of IL-10 and can suppress immune activation [32]. We hypothesized that since the BCL1 tumor cells are malignant B cells, and that they are immunosuppressive in mice [33], they might exhibit characteristics of Bregs. To explore this possibility, we stained spleen cells from the BCL1 tumor-bearing mice with antibodies against BCL1-Id, and the cell surface markers, CD1d and CD5 that identify the B10 subset of Bregs [23]. An examination of the co-expression of CD1d and CD5 by flow cytometry yielded 3 distinct subsets of B cells in the spleen (Fig 6A). Of the 3 subsets, only the CD1dhiCD5+ subset, which corresponds to B10 Bregs, also co-stained with the anti-BCL1-Id. Moreover, a similar Breg phenotype was also observed using in the spleen cells from mice with dormant vs. actively dividing BCL1 tumor (Fig 6B), suggesting that immunization does not alter the Breg phenotype of the tumor cells. Moreover, we observed that the BCL1.3B3 cell line (adapted for in vitro growth) [29] expressed the same Breg phenotype (Fig 6C).

Fig 6. BCL1 tumor cells express the characteristics of B10 Bregs.

Examination of a B10 Breg phenotype performed on spleen cells from mice injected with (A) BCL1 tumor cells only, (B) pre-immunized with BCL1-Id+ IgM and challenged with BCL1 tumor cells, and (C) in vitro-adapted BCL1 tumor cells. The analysis shows 3 distinct subsets, of which the B10 Breg phenotype (CD1dhiCD5+) is unique to the BCL1-Id+ tumor cells. Representative plots of at least 3 or more independent experiments are shown. (D) Intracellular cytokine staining of spleen cells from mice challenged with BCL1 tumor cells (solid line) or naïve mice (dashed line). Histogram plots are representative of 3 independent experiments. (E) The cytokine profile of supernatants from BCL1.3B3 tumor cells following a 72 h culture period as determined by ELISA. Total values are shown as mean ± SEM from 2–3 experiments. ND, below detection limits.

Although BCL1 tumor cells secrete IL-10 they mediate T cell suppression primarily by inhibiting cell-cell contact

We next examined the tumor cells for secretion of IL-10, the signature CD1dhiCD5+ Breg cytokine [32]. Intracellular staining of BCL1 cells directly harvested from spleens and showed that they indeed produced IL-10. (Fig 6D). By comparison, normal splenic B cells did not produce measurable levels of IL-10, confirming that IL-10 production is confined to the BCL1 tumor cells. We further studied the cytokine profile of the tumor cells by examining levels of an array of cytokines by ELISA in cultured BCL1.3B3 cells. We found that BCL1.3B3 cells secreted high levels of IL-10, but not TGF-β another immunosuppressive cytokine, or the pro-inflammatory cytokines, IFN-γ or TNF-α (Fig 6E). Interestingly, the BCL1 tumor cells also secreted IL-6, which has been described to contribute to the impairment of immune responses in the tumor milieu [34].

As discussed earlier, CD8+ T cells were completely eliminated from the spleens of non-immunized BCL1 tumor-bearing mice (Fig 1D). Since the tumor cells expressed the phenotype and cytokine profile of B10 Bregs, we hypothesized that they either inhibited the proliferation of CD8+ T cells or actively killed them. To further explore this issue, we modified the standard Treg suppression assay by using the BCL1 tumor cells as suppressor cells. Purified BCL1 Id+ tumor cells were co-cultured in graded doses with CFSE-labeled CD8+ T cells for 72 hours. Cultures were analyzed for the proliferation of CD8+ cells using CFSE dilution. In the absence of BCL1 tumor cells, the majority of the CD8+ T cells underwent proliferation in vitro (Fig 7A). Interestingly, co-culturing CD8 T cells with equal numbers of tumor cells increased the proliferation of CD8+ T cells (Fig 7B). However, when examining the in vivo tumor microenvironment, we had observed that the number of BCL1 tumor cells was consistently >200-fold higher than the number of CD8+ T cells (Fig 1B and 1D). Therefore, for the in vitro assay, we adjusted the number of tumor and CD8+ T cells to numbers that would be more analogous to their physiological ratios. This resulted in a complete inhibition of the proliferation of the CD8+ T cells (Fig 7C). Taken together, these results lead us to hypothesize that when there are few tumor cells present, that they actually enhance the numbers of anti-tumor effector T cells. As the number of tumor cells increase and greatly outnumber these effector T cells, they can then kill them or inhibit their proliferation.

Fig 7. BCL1 tumor cells suppress the proliferation of CD8+ T cells in a contact-dependent manner.

The proliferation of CFSE-labeled CD8+ T cells was determined (A) alone, or (B) with equal numbers of BCL1 tumor cells (1:1) or (C) High ratios of BCL1 tumor cells to CD8+ T cells, as observed in the tumor milieu. (D) BCL1 tumor cells were prevented from making contact with CD8+ T cells by using Trans-well inserts. E, Addition of large numbers of spleen cells from naïve mice did not inhibit the proliferation of CD8+ T cells. F, Assessment of caspase-3 levels in CD8+ T cells following co-culture with graded doses of BCL1 tumor cells. Values in FACS plots represent the percentage of CD8+ T cells undergoing proliferation. Representative plots of 3 independent experiments are shown.

We also determined whether the T cell suppression was due to cell contact using the trans-well assay. We found that preventing contact between tumor cells and CD8+ T cells restored the proliferation of the latter (Fig 7D). This was not due to overcrowding in the cell culture since equal numbers of normal spleen cells had no such effect, although there were fewer rounds of cell division, as might be expected (Fig 7E). These results demonstrate that BCL1 tumor cells suppress the proliferation of CD8+ T cells primarily by cell-cell contact.

BCL1 tumor cells induce apoptosis in CD8+ T cells by activating caspase-3

To gain further insight into the mechanism by which BCL1 tumor cells eliminate CD8+ T cells, we examined caspase-3 activation in the CD8+ T cells following their co-culture with BCL1 tumor cells. Caspase-3 is a member of the family of effector caspases and its active form triggers the apoptosis pathway. Caspase-3 activation can be initiated in target cells by the binding of Fas-ligand (FasL) to its surface receptor, CD95 (Fas), which leads to subsequent activation of the caspase-3-mediated apoptosis [35]. Since BCL1 tumor cells express FasL (data not shown), we questioned whether tumor cell-mediated inhibition of CD8+ T cells was induced via the FasL-mediated caspase cascade. We therefore co-cultured purified CD8+ T cells with graded doses of BCL1.3B3 tumor cells for 5 or 48 time hours and assessed the activation of caspase-3 in CD8+ T cells by intracellular staining and flow cytometry. Our results show that there was no difference in caspase-3 activation at either 5 or 48 hours (data not shown). However, casapase-3 activation increased in CD8+ T cells when they were cultured with larger numbers of BCL1.3B3 tumor cells (10:1) demonstrating a clear trend of increased caspase-3 activation in CD8+ T cells cultured with larger numbers of BCL1 tumor cells (Fig 7F). Although adding anti-FasL antibody to the cultures did not inhibit or reduce levels of activated caspase-3. This might be due to limitations of in vitro tissue culture assays in blocking molecular signaling pathways. However, we cannot rule out a role for other death domain ligands such as TRAIL, which also trigger the caspase cascade. Regardless, our results suggest that BCL1 tumor cells inhibit CD8+ T cells at least in part by caspase-3-mediated apoptosis.


In this study we used an established mouse model of B cell lymphoma, BCL1, to examine the interaction between tumor cells and T lymphocyte subsets within the tumor microenvironment, i.e. the spleen. Inoculation of tumor cells into BALB/c mice results in rapid growth of the tumor in the spleen over a period of 2–4 months. The tumor cells finally spill out into the blood and lymph nodes [6,28]. Immunization of mice using the IgM-Id antibody elicits a potent and specific antibody-mediated anti-tumor response. When immunized mice are inoculated with BCL1 tumor cells, the tumor grows for a short period of time and then regresses into a dormant state that can last for the lifetime of the mice [36]. CD8+ T cells and IFN-γ can prolong tumor dormancy [10]. However, little is known about the role of subsets of T cells in the dynamic growth and/or dormancy of the tumor. Furthermore, it is unclear whether malignant BCL1 cells themselves have any effect on these T cells.

In order to gain insight into the role of T cells in the BCL1 tumor model, we studied T cell subsets in vivo and their activity as both effector cells and target cells. The major findings to emerge from this study are: 1. Immunization against the BCL1-specific antigen preserved the levels of CD4+, CD8+, and Treg T cell subsets even after tumor challenge. 2. Non-immunized mice with large tumor burdens had significantly fewer CD8+ T cells and Tregs in their spleens while the numbers of CD4+ T cells were normal. 3. Although Tregs were present in the spleens of tumor-bearing immunized mice, tumor growth never progressed to clinical disease. 4. There were small numbers of tumor cells in lymph nodes but the T cell numbers remained normal in all the different groups of mice. 5. As determined by ex vivo experiments, Tregs from the spleens of mice with dormant tumor cells had normal suppressive activity but did not inhibit the proliferation of, or IgM secretion by the tumor cells suggesting that they do not act directly on the tumor cells themselves. 6. The BCL1 tumor cells had the phenotype and cytokine profile of normal B10 Bregs. 7. BCL1 tumor cells suppressed the proliferation of CD8+ T cells in vitro and this suppression was dependent upon cell-cell contact and the likely involved activation of caspase-3.

Taken together, these results suggest that CD8+T cells in the spleen are stimulated to expand by small numbers of tumor cells and initially keep them in check. As the tumor cells outgrow the cytotoxic T cells, they eventually kill them by cell-cell contact. In contrast, when anti-Id is present the tumor cells are prevented from expanding at a rapid rate. As a result, the cytotoxic T cells kill them and the tumor cells therefore proliferate and are killed at the same rate leading to a steady state that we define as dormancy. If/when the titers of anti-Id wane, the tumor cells grow rapidly and escape dormancy by once again killing effector T cells and Tregs. Thus, there is a complex and time-dependent interplay between the neoplastic Bregs (which are cytotoxic for the effector T cells and Tregs), the anti-Id antibody and CD8+ cells (which are cytotoxic for the tumor cells), and the Tregs, (which kill the tumor-reactive CD8+ T cells) in the induction and maintenance of dormancy.

The major difference between mice harboring dormant vs. actively growing BCL1 tumor cells is that CD8+ T cells are virtually eliminated and Tregs are reduced in number in the latter situation. In vitro studies also demonstrated that large numbers of BCL1 cells suppress the growth of CD8+ T cells in a contact-dependent manner. Since BCL1 tumor cells express Fas-Ligand, binding to Fas on target cells likely initiates caspase-mediated apoptosis [35]. Our co-culture assays showed that high ratios of BCL1 tumor cells were needed to induce caspase-3 activation in CD8+ T cells suggesting that prolonged or repeated contact between BCL1 tumor cells and cytotoxic T cells might be required to kill the latter. This is consistent with our hypothesis that large numbers of BCL1 tumor cells are needed to eliminate cytotoxic T cells. Tregs and CD8+ T cells were not depleted from the inguinal lymph nodes, likely due to their small numbers and suggesting that the tumor-induced immunosuppressive environment was confined to the spleen. Hence, in actively growing tumors, effector T cells would be eliminated. In contrast, in dormant tumor or in tumor localized in lymph nodes, the tumor cells would not be present in sufficient numbers to kill all the effector cells. Thus, dormancy actually induces a steady state where the BCL cells divide and are killed at the same rate due to an "optimal" ratio of tumor cells to T cells. Although soluble IL-10 secreted by the BCL1 tumor cells alone was insufficient to prevent T cell proliferation it likely contributed to an immunosuppressive milieu.

Our results are consistent with those from Saito et al. who examined cells from patients with advanced melanoma [37]. In that report a significant loss of CD8+ T cells relative to other lymphocyte subsets was observed. They further noted that co-incubation of T cells with tumor cells led to a variety of functional impairments resulting in the activation of caspases and T cell apoptosis [37].

Taken together with these results, our studies demonstrate that rapidly proliferating tumor cells can kill cytotoxic and regulatory T cells in the tumor milieu. In contrast, BCL1 tumor cells, whether dormant or active, had no inhibitory effects on CD4+ T cells in the spleen. Total CD4+ T cells in the spleens of mice with active tumor growth were not significantly different than those in mice with dormant BCL1 tumor or no tumor. These results are consistent with those of Farrar et al. who showed that cellular anti-BCL1 responses did not require CD4+ T cells [8]. They also demonstrated that CD8+ but not CD4+ T cells contributed to the maintenance of BCL1 tumor dormancy. This might be explained by the possibility that subsets of CD4+ cells can express different levels of Fas and thus have varying responses to Fas [38]. Tuft et al. also reported that activation of cytotoxic T cells was independent of CD4+ T cells in several models of B lymphoma, including BCL1 [39]. Moreover, both studies showed that depletion of CD4+ T cells did not abrogate anti-BCL1 immunity. Hence, while CD4+ T cells are likely important for the initial activation of CD8+ T cells, once the latter are activated the former are no longer needed. That in turn would infer that APCs for memory CD8+ effector T cells are the tumor cells themselves or other APCs such as macrophages. This is consistent with a report describing the activation of memory-effector cytotoxic T cells [39].

An important finding to emerge from our study is that mice with large BCL1 tumor burdens also had fewer Tregs in their spleens than mice harboring dormant BCL1 tumor cells. Our results differ from those using other tumor models where increases in Tregs correlate with tumor expansion and disease progression. Other studies have suggested that Tregs support tumor growth by inhibiting anti-tumor immunity [40]. Moreover, clinical studies have reported increased numbers of Tregs in tumors and draining lymph nodes in patients with solid tumors [13,16]. Yet, while the presence of greater numbers of Tregs has been associated with the progression of solid tumors, increased numbers of Tregs in patients with hematologic tumors does not always confer poor clinical outcomes [41,42]. Therefore, it is possible that rapidly growing neoplastic Bregs are unique in their ability to suppress or kill Tregs. However, the Treg profile that we describe here may also be unique to this particular model of B cell lymphoma and tumor dormancy. Although we found that the Tregs had no effects on BCL1 tumor cells in vitro even though they have been reported to directly suppress the activation of normal B cells [43], the activation of normal B cells versus proliferation of malignant B cells represent two very different situations.

The most intriguing finding was that the BCL1 tumor cells expressed the phenotype (CD1dhiCD5+) and cytokine profile (IL-10+) of B10 Bregs. These cells have been reported in both mice and humans [44,45]. Human Bregs are also CD19+CD1dhiCD5+ and are functionally immunosuppressive. They have been reported to inhibit autoimmune disorders [46]. A recent study further elucidated B regulatory functions by demonstrating shared characteristics between CLL, a common adult B cell leukemia, and human IL-10+ Bregs [47]. Notably, the ability of CLL cells to produce IL-10 appeared to influence disease progression [23] probably, in part, by immunosuppression. Indeed patients with CLL often succumb to infections. Interestingly, the clinical characteristics and histopathology of BCL1 tumor cells were described to be analogous to prolymphocytic leukemia or CLL in humans [48,49].

The data presented in this study offer new insights into the presence and function of normal Tregs and malignant Bregs. While the major mechanism for the establishment of dormancy appears to be signaling by anti-Id antibody [9], anti-Id does not eliminate all the tumor cells. However, once most of the tumor cells are eliminated, the interplay between the remaining effector and regulatory T cells and the tumor cells leads to the steady state that we define as "dormancy". When tumor “relapse” occurs, the tumor cells again grow, kill the effector T cells, immunosuppress the host (likely by IL-10 secretion), and result in death. Our results support the strategy of combining inhibitory anti-tumor antibodies or immunoconjugates with antibodies or drugs that can unleash the effector T cells in the host.


The authors thank Linda Berry for administrative assistance. The studies described were supported by the Cancer Immunobiology Center, the Horchow Foundation and the Patigian Chair.

Author Contributions

  1. Conceptualization: AB ESV.
  2. Data curation: AB LMP.
  3. Formal analysis: AB LMP ESV.
  4. Funding acquisition: ESV.
  5. Investigation: AB LMP.
  6. Methodology: AB LMP ESV.
  7. Project administration: AB ESV.
  8. Resources: ESV.
  9. Supervision: ESV.
  10. Validation: AB LMP.
  11. Visualization: AB.
  12. Writing – original draft: AB ESV.
  13. Writing – review & editing: AB LMP ESV.


  1. 1. Uhr JW, Marches R. Dormancy in a model of murine B cell lymphoma. Semin Cancer Biol. 2001; 11(4):277–83. doi: 10.1006/scbi.2001.0383. pmid:11513563
  2. 2. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LWMM, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA. 1998; 95(8):4589–94. pmid:9539782
  3. 3. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004; 10(24):8152–62. doi: 10.1158/1078-0432.CCR-04-1110. pmid:15623589
  4. 4. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA. 2006; 103(46):17361–5. doi: 10.1073/pnas.0608113103. pmid:17079488
  5. 5. Vitetta ES, Yuan D, Krolick K, Isakson P, Knapp M, Slavin S, et al. Characterization of the spontaneous murine B cell leukemia (BCL1). III. Evidence for monoclonality by using an anti-idiotype antibody. J Immunol. 1979; 122(5):1649–54. pmid:109513
  6. 6. Yefenof E, Picker LJ, Scheuermann RH, Tucker TF, Vitetta ES, Uhr JW. Cancer dormancy: isolation and characterization of dormant lymphoma cells. Proc Natl Acad Sci USA. 1993; 90(5):1829–33. pmid:8446596
  7. 7. Vitetta ES, Tucker TF, Racila E, Huang YW, Marches R, Lane N, et al. Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. Blood. 1997; 89(12):4425–36. pmid:9192767
  8. 8. Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW, et al. Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol. 1999; 162(5):2842–9. pmid:10072532
  9. 9. Racila E, Scheuermann RH, Picker LJ, Yefenof E, Tucker T, Chang W, et al. Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J Exp Med. 1995; 181(4):1539–50. pmid:7535341
  10. 10. Bluestone JA, Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol. 2005; 17(6):638–42. doi: 10.1016/j.coi.2005.09.002. pmid:16209918
  11. 11. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol. 2005; 6(4):353–60. doi: 10.1038/ni1181. pmid:15785761
  12. 12. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol. 2006; 176(2):705–10. pmid:16393950
  13. 13. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10(9):942–9. doi: 10.1038/nm1093. pmid:15322536
  14. 14. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 2006; 107(9):3639–46. doi: 10.1182/blood-2005-08-3376. pmid:16403912
  15. 15. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008; 15(10):2286–93.
  16. 16. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4 (+) CD25 (+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001; 61(12):4766–72. pmid:11406550
  17. 17. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 2006; 66(11):5716–22. doi: 10.1158/0008-5472.CAN-06-0261. pmid:16740709
  18. 18. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998; 10(12):1969–80. pmid:9885918
  19. 19. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998; 88(2):287–96.
  20. 20. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999; 190(7):995–1004. pmid:10510089
  21. 21. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4 (+) CD25 (+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001(5); 194:629–44. pmid:11535631
  22. 22. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, and et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007; 450(7169):566–9. doi: 10.1038/nature06306. pmid:18033300
  23. 23. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008; 28(5):639–50. doi: 10.1016/j.immuni.2008.03.017. pmid:18482568
  24. 24. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med. 2003; 197(4):489–501. doi: 10.1084/jem.20021293. pmid:12591906
  25. 25. Amu S, Saunders SP, Kronenberg M, Mangan NE, Atzberger A, Fallon PG. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J Allergy Clin Immunol. 2010; 125(5):1114–24. doi: 10.1016/j.jaci.2010.01.018. pmid:20304473
  26. 26. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res. 2011; 71(10):3505–15. doi: 10.1158/0008-5472.CAN-10-4316. pmid:21444674
  27. 27. Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med. 2013; 5(173):173ra23. doi: 10.1126/scitranslmed.3005407. pmid:23427243
  28. 28. Uhr JW, Tucker T, May RD, Siu H, Vitetta ES. Cancer dormancy: studies of the murine BCL1 lymphoma. Cancer Res. 1991; 51(18 Suppl):5045s–5053s. pmid:1884380
  29. 29. Gronowicz ES, Doss CA, Howard FD, Morrison DC, Strober S. An in vitro line of the B cell tumor BCL1 can be activated by LPS to secrete IgM1. J Immunol 1980; 125(3):976–80. pmid:6157730
  30. 30. Pop LM, Smallshaw JE, Tucker TF, Stevenson FK, Vitetta ES. Failure of vaccination with idiotypic protein or DNA, (+/-IL-2), the depletion of regulatory T cells, or the blockade of CTLA-4 to prolong dormancy in mice with BCL1 lymphoma. J Immunother. 2005; 28(6):525–34. pmid:16224269
  31. 31. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010; 11(12):1093–101. doi: 10.1038/ni.1952. pmid:20953201
  32. 32. DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci. 2010; 1183:38–57. doi: 10.1111/j.1749-6632.2009.05137.x. pmid:20146707
  33. 33. Layton JE, van der Hoven A, Uhr JW, Vitetta ES. Immunosuppression in the murine B cell leukemia, BCL1: Requirement for a suppressor 1 macrophage and a normal T cell. In: Vitetta ES, editor, B and T cell Tumors. Academic Press, New York; 1982. pp. 369.
  34. 34. Tsukamoto H, Senju S, Matsumura KS, Swain SL, Nishimura Y. IL-6-mediated environmental conditioning of defective Th1 differentiation dampens anti-tumour immune responses in old age. Nat Commun. 2015; 6:6702. doi: 10.1038/ncomms7702. pmid:25850032
  35. 35. MacKenzie SH, Clark AC. Targeting cell death in tumors by activating caspases. Curr Cancer Drug Targets. 2008; 8(2):98–109. pmid:18336192
  36. 36. Siu H, Vitetta ES, May RD, Uhr JW. Tumor dormancy. I. Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. J Immunol. 1986; 137(4):1376–82. pmid:3525678
  37. 37. Saito T, Dworacki G, Gooding W, Lotze MT, Whiteside TL. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res. 2000; 6(4):1351–64. pmid:10778963
  38. 38. Maksimow M, Santanen M, Jalkanen S, and Hänninen A. Responding naive T cells differ in their sensitivity to Fas engagement: early death of many T cells is compensated by costimulation of surviving T cells. Blood. 2003; 101(10):4022–8. doi: 10.1182/blood-2002-06-1904. pmid:12531803
  39. 39. Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol. 2002; 168(6):2720–8. pmid:11884438
  40. 40. Darrasse-Jèze G, Podsypanina K. How numbers, nature, and immune status of foxp3 (+) regulatory T-cells shape the early immunological events in tumor development. Front Immunol. 2013; 4:292. doi: 10.3389/fimmu.2013.00292. pmid:24133490
  41. 41. Kim WY, Jeon YK, Kim TM, Kim JE, Kim YA, Lee SH, et al. Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol. 2009; 20(10):1688–96. doi: 10.1093/annonc/mdp056. pmid:19542249
  42. 42. Tzankov A, Meier C, Hirschmann P, Went P, Pilleri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008; 93(2):193–200. doi: 10.3324/haematol.11702. pmid:18223287
  43. 43. Lim HW, Hillsamer P, Banham AH, Kim CH. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol. 2005; 175(7):4180–3. pmid:16177055
  44. 44. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 2010; 32(1):129–40. doi: 10.1016/j.immuni.2009.11.009. pmid:20079667
  45. 45. Iwata Y, Matsushita T, Horikawa M, DiLlilo DB, Yanaba K, Venturi GM, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011; 117(2):530–41. doi: 10.1182/blood-2010-07-294249. pmid:20962324
  46. 46. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012; 30:221–41. doi: 10.1146/annurev-immunol-020711-074934. pmid:22224776
  47. 47. DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y, et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia. 2013; 27(1):170–82. doi: 10.1038/leu.2012.165. pmid:22713648
  48. 48. Slavin S, Strober S. Spontaneous murine B-cell leukemia. Nature. 1978; 272(5654):624–6. pmid:306069
  49. 49. Krolick KA, Isakson PC, Uhr JW, Vitetta ES. BCL1, a murine model for chronic lymphocytic leukemia: use of the surface immunoglobulin idiotype for the detection and treatment of tumor. Immunol Rev. 1979; 48:81–106. pmid:94899